Regeneron News Highlights Rare Disease Focus And Valuation Gap

2026-03-02 07:42:06

Abstract generation in progress

Regeneron Pharmaceuticals received FDA approval for Dupixent to treat allergic fungal rhinosinusitis and Priority Review for garetosmab for fibrodysplasia ossificans progressiva, emphasizing its focus on targeted biologic therapies for rare diseases. The company’s stock trades below analyst targets and an estimated fair value, with recent positive short-term price momentum. Investors should monitor Dupixent’s uptake, garetosmab’s review progress, and regulatory outcomes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.